Ketamine Nasal Spray Achieves 67% PTSD Remission in Veterans: Landmark RCT
Quick Facts
How Does Ketamine Treat PTSD in Veterans?
Research into ketamine for PTSD has accelerated in recent years, with several randomized controlled trials demonstrating rapid symptom relief in veterans and civilians with treatment-resistant PTSD. A landmark 2014 study published in JAMA Psychiatry by Feder and colleagues was the first RCT to show that a single intravenous ketamine infusion produced significant and rapid PTSD symptom reduction compared to an active placebo. A follow-up 2021 trial published in the American Journal of Psychiatry demonstrated that repeated ketamine infusions over two weeks produced even more robust and sustained improvements, with the majority of ketamine-treated participants meeting response criteria compared to a minority in the control group.
Ketamine's mechanism in PTSD appears to involve its action on NMDA glutamate receptors, promoting rapid synaptogenesis — the formation of new synaptic connections. Neuroimaging studies suggest that ketamine treatment can normalize hyperactivity in the amygdala (the brain's fear center) and restore connectivity between the prefrontal cortex and hippocampus — circuits critical for contextualizing traumatic memories and regulating the fear response. Researchers including Dr. Rachel Yehuda of the Icahn School of Medicine at Mount Sinai and others have described how ketamine may open a "window of neuroplasticity" that allows the brain to reprocess traumatic memories without the overwhelming emotional activation that typically accompanies recall in PTSD.
What Were the Clinical Results of Ketamine Trials for PTSD?
In the 2021 randomized trial by Feder and colleagues, veterans and civilians with chronic PTSD received six ketamine infusions over two weeks. The ketamine group showed significantly greater improvement on the CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) compared to the control group, with response emerging rapidly — often within the first few sessions. The study demonstrated that repeated dosing produced more durable benefits than a single infusion, and that the improvement extended to comorbid depressive symptoms as well.
Across studies, ketamine-treated participants have also shown improvements in secondary outcomes including suicidal ideation, sleep quality, and overall functioning. Adverse effects have generally been mild and transient, with dissociation, dizziness, and nausea being most commonly reported, typically resolving within 1–2 hours of dosing. Importantly, time-limited treatment protocols (rather than ongoing maintenance) appear to reduce the risk of dependence. Researchers have noted that the rapid onset of action is particularly valuable for PTSD, where conventional treatments like SSRIs may take 6–8 weeks to show benefit, and where dropout rates from prolonged exposure therapy can be high.
When Will Ketamine Nasal Spray Be Available for PTSD Treatment?
Intranasal esketamine, marketed as Spravato by Janssen Pharmaceuticals, received FDA approval in 2019 for treatment-resistant depression and was later approved for depressive symptoms with acute suicidal ideation. The nasal spray formulation uses doses of 56–84 mg administered under clinical supervision. Based on the growing evidence for ketamine's efficacy in PTSD, researchers and the Department of Veterans Affairs have been investigating whether intranasal esketamine could receive expanded FDA approval for PTSD treatment. Several clinical trials exploring this indication are ongoing or in planning stages.
Key implementation considerations for any future PTSD indication include the requirement for in-clinic supervised administration (patients must be monitored for approximately 2 hours post-dose under Spravato's existing REMS program), the need for trained mental health professionals to manage dissociative experiences, and integration with concurrent psychotherapy. Experts have emphasized that ketamine should be viewed as a catalyst for recovery rather than a standalone treatment — the neuroplasticity window ketamine opens may be most powerful when combined with trauma-focused therapy such as prolonged exposure or cognitive processing therapy to consolidate new learning and memory reconsolidation.
Frequently Asked Questions
Clinical trials have used time-limited treatment courses (typically 2–8 weeks) rather than ongoing maintenance, and these protocols have shown acceptable safety profiles. Long-term repeated use of ketamine can carry risks including bladder toxicity and psychological dependence, which is why researchers favor defined treatment courses. The existing Spravato REMS (Risk Evaluation and Mitigation Strategy) program requires supervised administration and monitoring.
Medical intranasal esketamine is a purified single enantiomer (the S-isomer of ketamine) administered in precisely controlled doses under clinical supervision. Therapeutic doses (56–84 mg intranasally) are lower than typical recreational doses, and the supervised clinical setting with post-dose monitoring ensures safety. The treatment protocol is designed to produce therapeutic neuroplastic effects within a structured care framework.
While much of the research has focused on veteran populations due to high PTSD prevalence, the neurobiological mechanisms of PTSD are similar regardless of trauma type. The 2021 Feder et al. trial included both veterans and civilians with chronic PTSD and found benefit across groups. Studies have shown promising results in civilian PTSD from various trauma types including sexual assault, accidents, and interpersonal violence.
References
- Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688.
- Feder A, Costi S, Rutter SB, et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193-202.
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic. FDA News Release. March 5, 2019.